Accessibility Menu
 
Lyell Immunopharma logo

Lyell Immunopharma

(NASDAQ) LYEL

Current Price$19.71
Market Cap$458.45M
Since IPO (2021)-94%
5 YearN/A
1 Year+66%
1 Month-16%

Lyell Immunopharma Financials at a Glance

Market Cap

$458.45M

Revenue (TTM)

$36.00K

Net Income (TTM)

$274.45M

EPS (TTM)

$-15.17

P/E Ratio

-1.30

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$19.71

Volume

3,198

Open

$20.60

Previous Close

$19.71

Daily Range

$19.37 - $20.70

52-Week Range

$7.65 - $45.00

LYEL News

LYEL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lyell Immunopharma

Industry

Biotechnology

Employees

161

CEO

Lynn Seely, MD

Headquarters

South San Francisco, CA 94080, US

LYEL Financials

Key Financial Metrics (TTM)

Gross Margin

-66%

Operating Margin

-5660%

Net Income Margin

-7624%

Return on Equity

-87%

Return on Capital

-70%

Return on Assets

-81%

Earnings Yield

-76.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$458.45M

Shares Outstanding

23.31M

Volume

3.20K

Short Interest

0.00%

Avg. Volume

105.88K

Financials (TTM)

Gross Profit

$11.50M

Operating Income

$203.77M

EBITDA

$192.24M

Operating Cash Flow

$150.02M

Capital Expenditure

$780.00K

Free Cash Flow

$150.80M

Cash & ST Invst.

$247.22M

Total Debt

$41.92M

Lyell Immunopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$6.00K

-45.5%

Gross Profit

$2.39M

-21836.4%

Gross Margin

-398.50%

N/A

Market Cap

$458.45M

N/A

Market Cap/Employee

$1.53M

N/A

Employees

300

N/A

Net Income

$140.72M

+26.7%

EBITDA

$59.47M

-3.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$205.30M

-34.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$41.92M

-17.8%

Short Term Debt

$0.00

-100.0%

Return on Assets

-80.71%

N/A

Return on Invested Capital

-70.11%

N/A

Free Cash Flow

$61.19M

-29.4%

Operating Cash Flow

$60.83M

-28.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LRMRLarimar Therapeutics, Inc.
$4.62-4.74%
ALLOAllogene Therapeutics, Inc.
$2.26-6.22%
KYTXKyverna Therapeutics, Inc.
$7.80-2.86%
AMRNAmarin Corporation plc
$14.45-1.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.56-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$87.42+0.06%
IBITiShares Bitcoin Trust
$37.40-0.04%

Questions About LYEL

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.